Natera, Inc. $NTRA Holdings Lifted by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 28.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,411 shares of the medical research company’s stock after buying an additional 8,088 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Natera were worth $6,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter valued at approximately $33,000. Sound Income Strategies LLC boosted its position in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC bought a new position in shares of Natera in the third quarter worth $46,000. V Square Quantitative Management LLC acquired a new position in shares of Natera during the second quarter valued at $53,000. Finally, N.E.W. Advisory Services LLC grew its position in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after buying an additional 226 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on NTRA. Morgan Stanley boosted their price target on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. BTIG Research upped their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Barclays raised their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Stephens lifted their target price on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,590 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $373,650.00. Following the transaction, the chief executive officer owned 219,150 shares in the company, valued at $51,500,250. The trade was a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 293 shares of the company’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $68,855.00. Following the completion of the transaction, the insider directly owned 144,699 shares in the company, valued at approximately $34,004,265. The trade was a 0.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 509,657 shares of company stock worth $113,349,092. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $241.58 on Monday. The firm has a 50 day simple moving average of $234.18 and a 200 day simple moving average of $191.61. The company has a market cap of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. The business’s quarterly revenue was up 34.7% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.